niran singh's comment on DPHARMA. All Comments
niran singh
Like · Reply
Likely a lot more upside now considering US slapping tariffs on most SEA and ASEAN countries. New plant and capacity helps with new order take up... Hope Dpharma Commercial team has been aggressively lobbying in the last months to capitalise this opportunity
Report
Show more
2 months · translate ·
M K Wong
Biggest client for this company is msia govt hospital. Tarrif or not, this won't change. Client won't buy from Ah Kaw or Muthu, this is called kulitfication. Biggest shareholder is EPF, PNB... Combined more than 51%.
2 Like · 2 months · translate
Yike
ubat can expired got risk
Like · 2 weeks · translate
M K Wong
So... Which listed Co dont have any risk? All got risk.. Competition risk, currency risk, credit risk, etc. Who don't have?
Like · 2 weeks · translate
Yike
only bursa 1818 solo
Like · 2 weeks · translate
M K Wong
If you read their annual report... They too listed out their own risk. There are no company which are risk free.
Like · 2 weeks · translate
Yike
1818 likes reit already they fixed income is collect annual fee
Like · 2 weeks · translate
Yike
if more and more Ah Kaw Ah mau easily listing sure fat2
Like · 2 weeks · translate
小吴
Risk is opportunity
Like · 2 weeks · translate